Johnson & Johnson's Janssen arm is dialing up research through its Disease Interception Accelerator (DIA), a unit focused on predicting and preventing certain diseases through new diagnostic and therapeutic approaches. The company is kicking off two new projects for COPD and gestational diabetes aimed at uncovering the biological underpinnings of the diseases.
Immuno-oncology drugmakers Bristol-Myers Squibb and Merck have been quick to start up combination studies in an effort to expand the reach of their treatments and get ahead in an already heated market race. But other horses are preparing to enter the contest--and they've locked down more combo trials of their own.
Genentech and Johnson & Johnson are joining hands on another checkpoint combo program, matching Darzalex (daratumumab) and the PD-L1 drug atezolizumab for an unidentified solid tumor as well as multiple myeloma, where Darzalex is already approved for use.
How many drugmakers are delivering valuable new meds to the marketplace, saleswise? All too few, says innovation researcher and ex-Big Pharma manager Bernard Munos. In fact, the only two Big Pharmas with a decent track record these days are Johnson & Johnson and Bristol-Myers Squibb.
Johnson & Johnson wants to put litigation to rest over its power morcellator devices, and it wants to do it quickly. To accomplish this goal, the company is settling a number of suits claiming that its product, which J&J; has since pulled from the market, harmed women by spreading cancer.
The U.K. cost watchdogs at the National Institute for Health and Care Excellence have said they couldn't fund Johnson & Johnson's prostate cancer drug Zytiga for pre-chemo treatment because it was too expensive. Now J&J; has stepped forward with some discounts, so NICE is changing its tune.
The U.K.'s cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), has said it'd like to recommend Johnson & Johnson's prostate cancer drug Zytiga as a pre-chemo treatment, but Zytiga was just too expensive. Now NICE is changing its tune, agreeing to fund the med as long as J&J; delivers some discounts.
Johnson and Johnson's Stelara is facing fierce new competition in the psoriasis arena. But the New Jersey drugmaker is looking for ways the med can make its mark in other disease areas, and it's touting new data that could help it get there.
At the Barclays Global Healthcare Conference on March 17, Johnson & Johnson highlighted a consumer medical device focus, particularly in emerging markets, alongside 6 device areas of innovation that are expected to undergird growth in the segment for the conglomerate going forward.
Johnson & Johnson is facing a dark chapter in its legal saga over its Pinnacle devices. A federal jury ordered the company to fork over $500 million to 5 plaintiffs who claimed injuries from J&J;'s metal-on-metal hip implants.